Scholarlink

Background <p>Urothelial carcinoma (UC) is a malignancy of the urinary tract characterized by a high recurrence rate, imposing a substantial healthcare burden. Although cystoscopy and ureteroscopy remain the diagnostic gold standards, their invasive nature causes considerable discomfort during surveillance. Somatic mutations in the promoter region of the telomerase reverse transcriptase (<i>TERT</i>) gene are common events in UC and serve as promising noninvasive urinary biomarkers. This study aimed to evaluate the diagnostic utility of combining urinary <i>TERT</i> promoter mutation detection with cytology for UC diagnosis and surveillance, potentially serving as an indicator for cystoscopy application.</p> Methods <p>In this prospective study, 414 samples were collected, including 307 clinical patients, 25 non-tumorous hematuria patients, and 81 healthy controls. Droplet digital PCR (ddPCR) was used to detect <i>TERT</i> promoter mutations (C228T, C250T) in urinary cell-free DNA (cfDNA), alongside conventional cytology for comparison and combination analysis.</p> Results <p>The sensitivity and specificity of <i>TERT</i> promoter mutation detection were 48.6% and 84.7%, respectively, whereas those of cytology were 36.8% and 96.6%, respectively. Combining <i>TERT</i> mutation detection with cytology significantly improved diagnostic performance (sensitivity = 70.8%, specificity = 81.4%, AUC = 0.868). The mutant allele fraction (MAF) of <i>TERT</i> promoter mutations in UC patients was significantly higher than that in controls and showed an increasing trend with disease severity.</p> Conclusions <p>Urinary <i>TERT</i> promoter mutation detection, particularly when integrated with cytology, enhances the diagnostic sensitivity and overall accuracy for UC. The MAF of <i>TERT</i> promoter mutations correlated with disease severity, indicating potential clinical utility. This combined noninvasive assay may serve as a practical adjunct for UC diagnosis and surveillance, complementing conventional cystoscopy in clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月25日

查看全文
  • Xiaochen Zhi,
  • Zulihumaer Aizimuaji,
  • Nan Hu,
  • Sheng Ma,
  • Haiyang Li,
  • Xingang Bi,
  • Daohong Li,
  • Aixia Hu,
  • Huiqin Guo,
  • Weiqi Rong,
  • Ting Xiao,
  • Huan Zhao

摘要

Background

Urothelial carcinoma (UC) is a malignancy of the urinary tract characterized by a high recurrence rate, imposing a substantial healthcare burden. Although cystoscopy and ureteroscopy remain the diagnostic gold standards, their invasive nature causes considerable discomfort during surveillance. Somatic mutations in the promoter region of the telomerase reverse transcriptase (TERT) gene are common events in UC and serve as promising noninvasive urinary biomarkers. This study aimed to evaluate the diagnostic utility of combining urinary TERT promoter mutation detection with cytology for UC diagnosis and surveillance, potentially serving as an indicator for cystoscopy application.

Methods

In this prospective study, 414 samples were collected, including 307 clinical patients, 25 non-tumorous hematuria patients, and 81 healthy controls. Droplet digital PCR (ddPCR) was used to detect TERT promoter mutations (C228T, C250T) in urinary cell-free DNA (cfDNA), alongside conventional cytology for comparison and combination analysis.

Results

The sensitivity and specificity of TERT promoter mutation detection were 48.6% and 84.7%, respectively, whereas those of cytology were 36.8% and 96.6%, respectively. Combining TERT mutation detection with cytology significantly improved diagnostic performance (sensitivity = 70.8%, specificity = 81.4%, AUC = 0.868). The mutant allele fraction (MAF) of TERT promoter mutations in UC patients was significantly higher than that in controls and showed an increasing trend with disease severity.

Conclusions

Urinary TERT promoter mutation detection, particularly when integrated with cytology, enhances the diagnostic sensitivity and overall accuracy for UC. The MAF of TERT promoter mutations correlated with disease severity, indicating potential clinical utility. This combined noninvasive assay may serve as a practical adjunct for UC diagnosis and surveillance, complementing conventional cystoscopy in clinical practice.